Aug 2026· Theoretical and Natural Science· 0 citations
TL;DR
This review summarizes how the three canonical UPR branches establish a persistent adaptive state under chronic ER stress and discusses the molecular mechanisms by which UPR signaling maintains proteostasis, reprograms cellular metabolism, alleviates oxidative stress, and coordinates autophagy.
Abstract
The unfolded protein response (UPR) is a homeostatic protective mechanism activated in response to endoplasmic reticulum (ER) stress. However, once co-opted by cancer cells, its function extends far beyond maintaining proteostasis and becomes an important regulator of tumor progression. This review summarizes how the three canonical UPR branches establish a persistent adaptive state under chronic ER stress. It discusses the molecular mechanisms by which UPR signaling maintains proteostasis, reprograms cellular metabolism, alleviates oxidative stress, and coordinates autophagy. Thereby it allows cancer cells to survive in hostile microenvironments. The review further examines how these adaptive programs support tumor metastasis by promoting anoikis resistance, epithelial-mesenchymal plasticity, and tumor dormancy, which also enhances resistance to chemotherapy and immunotherapy. Current evidence suggests that cancer cell survival, metastasis, and therapy resistance are not independent consequences of UPR activation, but interconnected manifestations of a unified stress adaptation strategy driven by the UPR. By clarifying how cancer cells exploit UPR signaling and its underlying mechanisms, this review aims to provide insights into potential specific therapeutic opportunities for cancer.
How cells balance this tightrope between adaptation and cell death in the context of cancer is dissected, and how UPR signaling drives angiogenesis, metastasis, immune-evasion, and chemoresistance is explored before finally discussing its therapeutic potential.
This review integrates recent mechanistic insights into UPR-driven tumor progression, including pathway crosstalk, immune regulation, and immunotherapy resistance, with advances in small-molecule inhibitors, while critically evaluating their therapeutic potential and translational challenges in cancer treatment.
Meizhen Lin, Zhijie Li· Frontiers in Immunology· 0 citations
Current evidence is brought together to provide a comprehensive understanding of how CMA contributes to the Hallmarks of Cancer, including sustained proliferative signaling, resistance to cell death, metabolic reprogramming, invasion and metastasis, immune evasion, and the enabling characteristics of genome instability...
Meenakshi Tiwari, Lokendra Kumar Sharma, Bandana Chakravarti et al.· Frontiers in Oncology· 0 citations
A simple clearance to resistance framework is proposed that links acute protective stress responses, chronic tumor-promoting adaptation, and naturally evolved cancer resistance, and naturally evolved cancer resistance by cancer resistant subterranean mammals.
Yan-Dong Xu, Yang Zhao· Ageing and Cancer Research &...· 0 citations
Current and emerging therapeutic strategies aimed at disrupting proteostasis networks, including proteasome inhibitors, UPR-targeted agents, chaperone-directed therapies, and novel targeted protein degradation technologies are examined.
This framework may guide more precise intervention along the RCD–macrophage axis and evaluate nanomedicine strategies that coordinate tumor-selective RCD with macrophage regulation while emphasizing limitations in cell-type specificity, safety, patient selection and clinical evidence.
Xiao-Tang Duan, Pei-Ling Ma, X. Ao et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.